(Q38137830)

29 August 2017

title

Recent advances: Personalised use of current Crohn's disease therapeutic options (English)

1 reference

29 August 2017

1 reference

1

1 reference

29 August 2017

3

Paul Rutgeerts

1 reference

29 August 2017

2

Marc Ferrante

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

62

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1511-1515

1 reference

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Factors affecting outcomes in Crohn's disease over 15 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

The molecular classification of the clinical manifestations of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Gene expression signature for recurrence in stage III colorectal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

A CD8+ T cell transcription signature predicts prognosis in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2012-303958

10.1136/GUTJNL-2012-303958

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference